drugset / Trial / NCT00838903

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

NCT00838903

Phase 3 Completed 1049 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.

Timeline

Start
2009-02
Primary completion
2012-01
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glimepiride Small molecule
Comparator Sitagliptin Small molecule
Subject albiglutide Peptide
Background Metformin Small molecule